Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib
Maraj I, Hernandez-Ilizaliturri F, Chisti M, Czuczman M. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal Of Clinical Oncology 2009, 27: 8576-8576. DOI: 10.1200/jco.2009.27.15_suppl.8576.Peer-Reviewed Original ResearchRituximab-sensitive cell linesRituximab-resistant cell linesCell linesB-cell lymphomaBcl-2 family membersPatient-derived tumor cellsChemotherapy agentsNHL cell linesMonoclonal antibodiesPatient-derived tumour cellsBcl-xL geneCellular processesTumor cellsEffects of LBH589Polymerase chain reactionGene transcriptionGene expressionTarget proteinsAlamar Blue reductionMitochondrial potentialAntitumor activityNegative selectionSequence of administrationQualitative polymerase chain reactionCell titer